Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Recruiting · NCT06790784 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Proliferative Diabetic Retinopathy (PDR) | Recruiting | Phase 3 | 2026-09-18 | NCT06790784 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Jaeb Center for Health Research | 37 |
| National Eye Institute (NEI) | 122 |
34 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.